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The molecular underpinnings of the dissociation of cognitive performance and neuropatho-
logical burden are poorly understood, and there are currently no known genetic or epigenetic
determinants of the dissociation.
Methods and findings
“Residual cognition” was quantified by regressing out the effects of cerebral pathologies and
demographic characteristics on global cognitive performance proximate to death. To identify
genes influencing residual cognition, we leveraged neuropathological, genetic, epigenetic,
and transcriptional data available for deceased participants of the Religious Orders Study
(n = 492) and the Rush Memory and Aging Project (n = 487). Given that our sample size
was underpowered to detect genome-wide significance, we applied a multistep approach to
identify genes influencing residual cognition, based on our prior observation that indepen-
dent genetic and epigenetic risk factors can converge on the same locus. In the first step
(n = 979), we performed a genome-wide association study with a predefined suggestive p <
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10−5, and nine independent loci met this threshold in eight distinct chromosomal regions.
Three of the six genes within 100 kb of the lead SNP are expressed in the dorsolateral pre-
frontal cortex (DLPFC): UNC5C, ENC1, and TMEM106B. In the second step, in the subset
of participants with DLPFC DNA methylation data (n = 648), we found that residual cognition
was related to differential DNA methylation of UNC5C and ENC1 (false discovery rate <
0.05). In the third step, in the subset of participants with DLPFC RNA sequencing data (n =
469), brain transcription levels of UNC5C and ENC1 were evaluated for their association
with residual cognition: RNA levels of both UNC5C (estimated effect = −0.40, 95% CI −0.69
to −0.10, p = 0.0089) and ENC1 (estimated effect = 0.0064, 95% CI 0.0033 to 0.0096, p =
5.7 × 10−5) were associated with residual cognition. In secondary analyses, we explored the
mechanism of these associations and found that ENC1 may be related to the previously
documented effect of depression on cognitive decline, while UNC5C may alter the composi-
tion of presynaptic terminals. Of note, the TMEM106B allele identified in the first step as
being associated with better residual cognition is in strong linkage disequilibrium with
rs1990622A (r2 = 0.66), a previously identified protective allele for TDP-43 proteinopathy.
Limitations include the small sample size for the genetic analysis, which was underpowered
to detect genome-wide significance, the evaluation being limited to a single cortical region
for epigenetic and transcriptomic data, and the use of categorical measures for certain non-
amyloid-plaque, non-neurofibrillary-tangle neuropathologies.
Conclusions
Through a multistep analysis of cognitive, neuropathological, genomic, epigenomic, and
transcriptomic data, we identified ENC1 and UNC5C as genes with convergent genetic, epi-
genetic, and transcriptomic evidence supporting a potential role in the dissociation of cogni-
tion and neuropathology in an aging population, and we expanded our understanding of the
TMEM106B haplotype that is protective against TDP-43 proteinopathy.
Author summary
Why was this study done?
• Only a part of cognitive impairment in older adults is explained by common neuropa-
thologies such as amyloid plaques, neurofibrillary tangles, stroke, or Lewy bodies found
in Parkinson disease and some forms of dementia.
• Understanding the molecular basis of dissociation between cognitive outcomes and
neuropathological burden is of critical importance in understanding prognosis and in
designing clinical trials to prevent dementia.
• Animal studies cannot fully address this complex discrepancy between cognition and
neuropathology, and a well-powered large-scale genome-wide association study with
detailed cognitive and pathological phenotypes is not yet available.
• The availability of genetic, epigenetic, and transcriptomic data from two longitudinal
cohorts with quantitative cognitive and pathological assessments enabled us to look for
convergence of different molecular features onto certain target genes.
Genes associated with residual cognition
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What did the researchers do and find?
• In two well-characterized cohorts of aging (the Religious Orders Study and the Rush
Memory and Aging Project), we first captured the gap between cognitive performance
proximate to death and neuropathological burden for each individual (“residual
cognition”).
• Then, we performed sequential analyses including a genome-wide association study
(step 1), in which we identified loci that were further analyzed for association of their
methylation pattern (step 2) and brain RNA expression (step 3) with residual cognition.
• We identified two genes (UNC5C and ENC1) with converging evidence from all three
analytic steps, and also showed that a previously reported risk gene for frontotemporal
lobar degeneration, TMEM106B, might play a role in the dissociation of cognition and
neuropathology in older adults. Further, UNC5C brain expression level was correlated
with presynaptic protein levels, while ENC1 brain expression level was correlated with
depressive symptoms.
What do these findings mean?
• ENC1, UNC5C, and TMEM106B had converging evidence suggesting that they might
have a role in determining cognitive resilience in the aging population, which is affected
by Alzheimer disease, stroke, and other neuropathologies.
• These genes should be studied further to expand our understanding of molecular mech-
anisms relevant to cognitive resilience that could be translated into prognostic and ther-
apeutic tools for dementia prevention.
Introduction
It is well known that cognitive impairment in older adults is only partially explained by com-
mon neuropathologies such as Alzheimer disease (AD), stroke, and Lewy body disease [1–4].
Previous studies have shown that the majority of the variability in cognitive decline is unex-
plained, even when quantitative indices of common neuropathologies and demographic vari-
ables are included in the model [1,2]. Although additional variability has been explained by
traits such as depressive symptoms [2,5] and by neuroimaging measures of brain tissue integ-
rity [6,7], a large part of the cognitive impairment in late life remains unexplained. Further
disentangling this dissociation of pathological burden and cognitive outcome is of critical
importance in understanding clinical heterogeneity in the patient population and in designing
treatments that can prevent progression into dementia.
To account for this dissociation, multiple mechanisms have been suggested: brain reserve
capacity [2,8,9], cognitive reserve [2,10], differential neuroglial reactions to pathology [11],
and other undetected pathophysiological processes [11–13]. Although prior studies have
shown that the synaptic density and brain expression levels of multiple proteins in various bio-
chemical pathways are correlated with resilient cognition [14,15], the molecular and genetic
underpinnings of the dissociation of cognition and pathology remain poorly understood, and
currently there are no known genetic or epigenetic determinants of the cognition–pathology
discordance [16].
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To identify genes that contribute to differential cognitive outcomes in the setting of neuro-
pathology, we leveraged data from two large and richly phenotyped longitudinal cohort stud-
ies, the Religious Orders Study (ROS) and the Rush Memory and Aging Project (MAP)
[17,18]. Similar to prior studies using data from ROS and MAP [1,2,4], we quantified the dis-
sociation of cognition proximate to death and neuropathology by capturing the residual of
global cognitive performance proximate to death after regressing out the effects of demo-
graphic characteristics and neuropathologies. We use the term “residual cognition” for this
quantified residual of global cognitive performance that captures the dissociation of cognition
and neuropathology.
We recently reported that both genetic and epigenetic variation can be independently
associated with neuritic plaque pathology in the same chromosomal locus: for example, we
see such convergence of molecular evidence in ATP binding cassette subfamily A member 7
(ABCA7) and bridging integrator 1 (BIN1) [19]. In this study, we designed a strategy involving
a multistep analysis to identify loci in which genetic and epigenetic variation converge to influ-
ence residual cognition. In the first step of the analysis, we performed a genome-wide associa-
tion study (GWAS) and identified independent loci meeting our predetermined threshold of
suggestive genetic association with residual cognition. Candidate genes were identified based
on proximity to the lead single nucleotide polymorphism (SNPs) from each locus and were
selected for further analysis based on expression in human frontal cortex (the region for which
we have additional epigenomic and transcriptomic data). For the second step, we examined
associations between residual cognition and differential DNA methylation of the candidate
genes in human frontal cortex. In the third step, we further validated the role of the selected
genes using transcriptional data from the same cortical region. This allowed us to identify
genes with converging evidence from genetic, epigenetic, and transcriptomic data regarding
their roles in determining the dissociation of cognition and neuropathology.
Methods
Participants
This study and the protocol for both ROS and MAP were approved by the institutional review
board of Rush University Medical Center, and each participant signed a written informed con-
sent and an Anatomical Gift Act document. Our participants came from two longitudinal
cohort studies of older persons, ROS and MAP. ROS, started in 1994, is a longitudinal cohort
study that enrolls Catholic nuns, priests, and brothers from more than 40 communities across
the United States. MAP, launched in 1997, is a longitudinal cohort study that enrolls partici-
pants with diverse backgrounds and socioeconomic status from continuous care retirement
communities throughout northeastern Illinois, as well as from individual homes across the
Chicago metropolitan area. Participants from both cohorts were free of known dementia at the
time of enrollment, and these two cohorts were designed and are managed by the same team
of investigators, who capture the same cognitive measures and conduct a structured, quantita-
tive neuropathological examination at a single site. Thus, the two cohorts were designed to be
used in combined analyses. At the time of our analyses in September 2014, 1,240 participants
had been enrolled in ROS, and 1,752 participants had been enrolled in MAP; 674 and 723 par-
ticipants from each study were deceased, respectively. The combined follow-up rate of these
studies was 97%, and the brain autopsy rate among deceased participants was 86%. Among the
deceased participants, 492 ROS participants and 487 MAP participants were of European
ancestry and had the complete neuropathological evaluation, cognitive testing measures, and
quality-controlled genotyping data required for our step 1 analysis (n = 979). Further details
about the ROS and MAP cohorts can be found in previous publications [17,18] and through
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the Rush Alzheimer’s Disease Center Research Resource Sharing Hub (https://www.radc.rush.
edu/home.htm).
Cognitive and neuropsychiatric phenotypes
Cognitive function was annually assessed in both the ROS and MAP cohorts via 19 cognitive
tests, of which 17 were distributed across five cognitive domains: episodic memory, semantic
memory, working memory, perceptual speed, and visuospatial ability (S2 Table). Annual mea-
sures of global cognitive performance were derived by averaging the z-scores from each of
these 17 annual tests [17,18,20]. We used global cognition proximate to death to derive resid-
ual cognition. Separately, the residual slope of global cognitive change and the residual slopes
of cognitive change in the five cognitive domains were derived through general linear mixed
models, controlling for age at enrollment, sex, and education, as previously described [21].
Diagnosis of AD dementia was made by a neurologist blinded to all postmortem data, after
reviewing all available clinical data at the time of death. Selected cases were also reviewed
through case conferences [13,17,18]. For most of the participants (n = 977), depressive symp-
toms were measured annually with a ten-item form of the Center for Epidemiologic Studies
Depression Scale (CES-D) [5]. Given the previously reported relationship between depression
and residual cognitive decline [2], this measure of depressive symptoms proximate to death
was used to explore the association of depression with genes implicated in residual cognition.
Genotyping data acquisition
Genotyping was performed on either the Affymetrix GeneChip 6.0 platform (1,878 partici-
pants, 909,600 SNPs) or the Illumina OmniQuad Express platform (456 participants, 730,525
SNPs). DNA was extracted from whole blood, lymphocytes, or frozen brain tissue, as previ-
ously described [22]. To minimize population admixture, only self-declared non-Latino indi-
viduals of European ancestry were genotyped. Then, genotyping data from both platforms
were processed using PLINK software, version 1.08p [23], with standard quality control (QC)
metrics such as genotype success rate > 0.95, Hardy–Weinberg equilibrium p> 0.001, and
misshap test < 1 × 10−9, as previously described [22,24,25]. EIGENSTRAT was used with
default settings to remove population outliers and to generate a genotype covariance matrix
[26], and closely related participants were removed. After these QC steps, 1,709 individuals
and 750,173 autosomal markers from the Affymetrix GeneChip 6.0 platform, and 382 individ-
uals and 627,742 autosomal markers from the Illumina OmniQuad Express platform were
used for imputation. Dosages for SNPs (>35 million) were imputed on the 1000 Genomes
reference (1000 Genomes Project interim phase 1 haplotypes, 2010–2011 data freeze), using
BEAGLE software, version 3.3.2 [27]. All GWAS analyses in ROS and MAP filtered SNPs
based on minor allele frequency (MAF) > 0.01 and imputation INFO score> 0.3, leaving
about 7 million SNPs that were analyzed. Of note, each individual included in our analysis had
non-missing genotype dosages of these quality-controlled markers, as any missing markers
were imputed. In the current study limited to 979 participants, 859 participants were genotyped
through the Affymetrix platform, and 120 participants were genotyped through the Illumina
platform. In addition, APOE genotyping was done through a separate sequencing procedure, as
previously described [17,18], and the resulting allele counts were used in our study.
Pathological phenotypes
The derivation of pathological variables has been previously described in detail [17,18]. Briefly,
each brain was inspected for ten common pathologies relating to loss of cognition in aging pop-
ulations: neurofibrillary tangles, neuritic plaques, diffuse plaques, Lewy bodies, macroscopic
Genes associated with residual cognition
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002287 April 25, 2017 5 / 23
infarcts, microscopic infarcts, atherosclerosis, arteriolosclerosis, cerebral amyloid angiopathy
(CAA), and hippocampal sclerosis [13,28–33]. More specifically, neurofibrillary tangles, neuritic
plaques, and diffuse plaques were counted and scaled in five brain regions: mid-frontal, tempo-
ral, inferior parietal, entorhinal cortex, and hippocampus CA1. Composite scores for each of
the three pathology types were derived by scaling the counts within each of the five regions, and
then taking the square root of the average of the regional scaled values to account for their posi-
tively skewed distribution [17,18,21]. CAA was graded on a five-level scale (0 to 4) in four neo-
cortical regions (mid-frontal, angular gyrus, inferior temporal gyrus, and calcarine cortex) and
averaged to derive a CAA score, as previously described [34]. Chronic macroscopic and micro-
scopic infarcts were each dichotomized as present or absent. Atherosclerosis was scored on a
four-level severity scale, and arteriolosclerosis was measured on a four-level scale by small vessel
pathologies in anterior basal ganglia [35]. Nigral, limbic, and neocortical Lewy bodies were
dichotomized as present or absent, as identified using immunohistochemistry. Hippocampal
sclerosis was recorded as either present or absent as evaluated with H&E stain. Pathological
diagnosis of AD was given for cases with high or intermediate likelihood of AD per the modi-
fied National Institute of Aging–Reagan Institute criteria [36]. For a subset of participants (n =
826), transactive response DNA-binding protein 43 kDa (TDP-43) proteinopathy was measured
and categorized into four steps of severity as previously described [37]: no inclusions (stage 0),
inclusions in amygdala only (stage 1), inclusions in amygdala as well as entorhinal cortex and/
or hippocampus CA1 (stage 2), and inclusions in amygdala, neocortex, and entorhinal cortex
and/or hippocampus CA1 (stage 3). In addition, a semi-quantitative six-point scale for the
severity of the TDP-43 cytoplasmic inclusions was rated as previously described (n = 812) [38].
DNA methylation and RNA sequencing data acquisition
In ROS and MAP, dorsolateral prefrontal cortex (DLPFC) was selected for initial multi-omics
data generation, as it is relevant to multiple common neuropathologies and cognitive pheno-
types in the aging population [22]. DNA methylation levels from the gray matter of DLPFC
were measured using the Illumina HumanMethylation450 BeadChip, and the measurements
underwent QC processing as previously described (e.g., detection p< 0.01 for all samples)
[19,22], yielding 708 participants with 415,848 discrete CpG dinucleotide sites with methyla-
tion measurement. Any missing methylation levels from any of quality-controlled CpG dinu-
cleotide sites were imputed using a k-nearest neighbor algorithm for k = 100 [19]. A subset of
648 participants in our study had quality-controlled genome-wide methylation data.
RNA was extracted from the gray matter of DLPFC, and next-generation RNA sequencing
(RNA-Seq) was done on the Illumina HiSeq for samples with an RNA integrity score > 5 and
a quantity threshold > 5 ug, as previously described [22,39]. We quantile-normalized the frag-
ments per kilobase of transcript per million fragments mapped (FPKM), correcting for batch
effect with Combat [39,40]. These adjusted FPKM values were used for analysis. A subset of
469 participants in our study had quality-controlled RNA-Seq data, and all of them had non-
missing values for the expression levels of the six genes identified in step 1.
Brain MRI data acquisition and processing
Ex vivo brain MRI data were available in a subset of 419 participants in our study. In secondary
analyses exploring phenotypic correlates of identified genes, we used a composite measure of
transverse relaxation rate (R2) that was previously shown to correlate with the residual slope of
global cognitive decline in ROS and MAP participants [6,7]. Data acquisition and processing
have been described in detail previously [7]. In brief, for each participant, each voxel’s R2 was
quantified from the spin echo images to generate an R2 map. Voxelwise linear regression was
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run with slope of cognitive decline as a dependent variable, R2 as an independent variable, and
neuropathological indices (AD, cerebrovascular disease, and Lewy body disease) and demo-
graphics (age, sex, and education) as covariates. After correcting for multiple testing, contigu-
ous clusters of voxels associated with the slope of global cognitive decline were identified, and
mean R2 values of the voxels in each cluster were calculated, which were averaged to generate a
composite R2 measure.
Presynaptic protein data acquisition and processing
For a subset of the study participants, presynaptic protein quantification (n = 315) and quanti-
tative protein–protein interaction (n = 295) assays were done from the gray matter of three
brain regions (hippocampus, mid-frontal cortex, and inferior temporal cortex), and an overall
standardized score was generated as previously described [15]. Among the measurements, we
selected Complexin-I, Complexin-II, and Syntaxin/SNAP-25 interaction for our secondary
analyses to explore phenotypic correlations with identified genes, given their previously re-
ported strong association with global cognitive function independent from pathological bur-
den [15]. For a secondary evaluation of the specificity of findings to inhibitory or excitatory
terminals, we also examined Munc18-1 long (M18L, GABAergic terminals) and short (M18S,
GABAergic and glutamatergic terminals) isoforms as previously described (n = 280) [41].
Statistical analysis
We defined “residual cognition” as the residual of global cognition proximate to death result-
ing from a multivariate linear model adjusting for demographic characteristics (age at death,
sex, education, study cohort) and ten common neuropathologies implicated in cognitive de-
cline in older people (neurofibrillary tangles, neuritic plaques, diffuse plaques, Lewy bodies,
macroscopic infarcts, microscopic infarcts, atherosclerosis, arteriolosclerosis, CAA, and hi-
ppocampal sclerosis) [13,28–33]. Of note, TDP-43 proteinopathy was not included in this
model, as the number of participants with TDP-43 measurement was limited at the time of the
analysis.
A GWAS (step 1) was performed on residual cognition, modeling residual cognition as the
dependent variable, genotype as the independent variable, and the top three principal compo-
nents derived from the genetic covariance matrix (EV1–3) as covariates. Using PLINK version
1.08p, a linear model assuming additive genetic effects was used, and separate analyses were
performed according to genotyping platform. These results were meta-analyzed using PLINK
to mitigate potential confounding effects due to the combination of platforms. We used a
genome-wide significance threshold of p< 5 × 10−8 and a suggestive threshold of p< 10−5,
given our modest sample size. To count the number of independent loci associated with re-
sidual cognition, we used PLINK to clump SNPs within the suggestive loci with linkage dis-
equilibrium (LD) r2 > 0.2 as a threshold. The SNP with the most significant association with
residual cognition within each independent locus was selected as the lead SNP for that locus.
The lead SNPs were looked up in the HaploReg database version 4.1 [42] to identify coding
variants in LD (r2 > 0.2) with each of them, and selected SNPs were interrogated with the
ChromHMM core 15-state model (15-state chromatin map model) from the Roadmap Epige-
nomics Project’s Human Epigenome Atlas [43,44] to assess their functional implications. Each
lead SNP was tested for cis-expressive quantitative trait locus (cis-eQTL) association with
genes within 100 kb of the SNP, as it has been reported that the majority of cis-regulatory vari-
ations are found within 100 kb of transcription start site (TSS) [45]. Then, among the genes
within 100 kb from each lead SNP, only those with non-zero brain expression in the majority
of participants (>80%) were selected for further DLPFC DNA methylation and RNA level
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analyses, as differential methylation would have greater functional implications in actively
transcribed genomic regions.
In order to assess differential DNA methylation of candidate genes (step 2), three steps
were followed, similar to a previous study [46]. In the first step, all CpGs within 100 kb of the
start and stop positions of the gene were tested with linear regression for association with
residual cognition. Similar to the GWAS, residual cognition was modeled as the dependent
variable, each CpG methylation level as an independent variable, and technical variables
(batch and mean bisulfite conversion) as covariates. In the second step, the p-values of all
CpGs were meta-analyzed into a single observed test statistic using Fisher’s method. Finally,
to get an empirical omnibus p-value for a given gene, 10,000 permutations were run (permut-
ing the outcome variable, residual cognition), and the observed test statistic was compared
to these randomly generated test statistics. False discovery rate (FDR) < 0.05 was used as a
threshold for statistical significance. For regions with significant association between residual
cognition and differential methylation, further analyses also adjusting for the lead SNP from
each region and EV1–3 were done to check whether genetic and epigenetic associations were
independent.
To analyze RNA expression data (step 3), linear regressions were applied with residual cog-
nition as the dependent variable, Combat-adjusted FPKM values as the independent variable,
and technical factors as covariates (RNA integrity score, log2[total aligned reads], postmortem
interval, and number of ribosomal bases).
We performed secondary analyses of each validated candidate gene. First, to assess whether
each validated candidate genetic locus is exerting its effect through a neurodevelopmental pro-
cess, the association of the lead SNP from each locus with global cognition at enrollment was
assessed, controlling for demographic variables. In addition, to explore the effect of candidate
genetic loci on cognitive decline, the residual slope of global cognition change (“global cogni-
tive decline”; data available in 924 participants) and the residual slope of cognitive change in
each of the five cognitive domains were tested for association with the lead SNPs from vali-
dated loci, with pathologies and EV1–3 as covariates. In addition, we tested the association
of each lead SNP and RNA level with traits previously shown to be associated with residual
cognition (depressive symptoms proximate to death, ex vivo brain MRI composite R2, and
presynaptic protein levels), controlling for demographics. As these secondary analyses were
to further characterize the selected loci that were identified through the primary analyses, a
threshold for significance of p< 0.05 was used, except when we tested for the association of
each lead SNP and RNA level with cognitive domains, pathologies, or presynaptic proteins,
where we used FDR< 0.05. To further investigate the relationship among the identified
TMEM106B SNP rs11509153A, TDP-43 proteinopathy, and residual cognition, we tested
whether rs11509153A has an independent effect on residual cognition when the analysis was
controlled for TDP-43 stage or a semi-quantitative severity scale. Methylation pattern and
RNA expression of GRN, a gene functionally downstream of TMEM106B [37,47], were also
tested for association with residual cognition.
Of note, there were six loci that were identified in step 1 but did not have DLPFC-expressed
adjacent genes and were therefore excluded from the step 2 and step 3 analyses. In an explor-
atory analysis, we examined their genetic association with residual cognitive decline. Moreover,
all representative SNPs identified in step 1 analyses were checked for cis-eQTL association in
various brain regions using the Genotype-Tissue Expression (GTEx) project database [48].
To obtain the variance explained of the different variable types, we followed a sequential
adjusted R-squared analysis. First, we calculated the adjusted R-squared by modeling the last-
visit global cognitive score versus the pathological and demographic variables. Then, to deter-
mine the variance explained by genetic, epigenetic, and transcriptomic data, we calculated the
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additional adjusted R-squared gained when modeling the last global cognitive score versus
pathological, demographic, and genetic/epigenetic/transcriptomic data (the top SNP for each
respective locus, the top respective CpGs, and RNA levels) for UNC5C, ENC1, and
TMEM106B.
Of note, all statistical analyses were done with R 3.2.1 (https://www.r-project.org/) unless
mentioned otherwise. Each analysis was limited to participants with non-missing values.
Results
Description of participants, data, and phenotypes
From a total of 1,397 deceased ROS and MAP participants, we included 979 deceased individ-
uals of European descent from ROS and MAP who had complete neuropathological evalua-
tion, cognitive testing measures, and genotyping data in our step 1 analysis. Of note, among
deceased participants, included and excluded participants had similar demographic character-
istics (S1 Table). Phenotypic and genetic data were measured and derived as described in the
Methods and previous studies [17,18,22]. In brief, global cognition was calculated from 17 dif-
ferent neuropsychological tests (S2 Table), and each participant underwent a structured, quan-
titative neuropathological examination at the time of death. The demographic characteristics
of the participants used in our analyses are reported in Table 1.
In this study, “residual cognition” was defined as the residual of global cognitive perfor-
mance proximate to death, after controlling for demographic characteristics (sex, age, years of
education, and study cohort) and for ten common cerebral pathologies (neurofibrillary tan-
gles, neuritic plaques, diffuse plaques, Lewy bodies, macroscopic infarcts, microscopic infarcts,
atherosclerosis, arteriolosclerosis, CAA, and hippocampal sclerosis). TDP-43 pathology was
initially available for only a subset of participants and was therefore not included in the deriva-
tion of residual cognition. We note that our approach captures not only the extent to which
someone might be performing better than expected but also the extent to which other individ-
uals are performing worse than expected, based on their pathological burden.
Genome-wide association study for residual cognition
In order to identify genetic effects on residual cognition, we performed a GWAS for this trait
(Fig 1) as a first step of our analyses. The minor allele of each lead SNP was used as the alter-
nate allele in this analysis; thus, in some cases the minor allele may be protective while in other
Table 1. Demographic characteristics of participants.
Characteristic ROS MAP Combined
Cohort size, n 492 487 979
Age (years) at enrollment, mean (SD) 78.3 (7.0) 83.5 (5.7) 80.9 (6.9)
Age (years) at death, mean (SD) 87.8 (6.8) 89.8 (5.8) 88.8 (6.4)
Female, n (percent) 308 (62.6%) 322 (66.1%) 630 (64.4%)
Education (years), mean (SD) 18.2 (3.3) 14.5 (2.8) 16.4 (3.6)
Diagnosis of AD dementia, n (percent) 209 (42.9%) 184 (38.1%) 393 (40.5%)
Pathological diagnosis of AD, n (percent) 312 (63.4%) 312 (64.1%) 624 (63.7%)
Last global cognition, mean (SD) −0.92 (1.26) −0.90 (1.11) −0.91 (1.19)
Among 979 participants, only 970 participants were evaluated for final diagnosis of AD dementia. Last global cognition is the measure of global cognitive
performance proximate to death (z-score derived from baseline mean and standard deviation).
AD, Alzheimer disease; MAP, Rush Memory and Aging Project; ROS, Religious Orders Study; SD, standard deviation.
https://doi.org/10.1371/journal.pmed.1002287.t001
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cases the minor allele may be deleterious in relation to residual cognition. Given our moderate
sample size, no variant met a threshold of genome-wide significance (p< 5 × 10−8); however,
67 variants across nine independent loci in eight distinct genomic regions met our predefined
threshold for suggestive results (p< 10−5) (S3 Table). The lead SNPs with the smallest p-value
within each independent locus are shown in Table 2. There were six genes within 100 kb of
these lead SNPs: unc-5 netrin receptor C (UNC5C), ectodermal-neural cortex 1 (ENC1), trans-
membrane protein 106B (TMEM106B), anterior gradient 2 (AGR2), anterior gradient 3 (AGR3),
and LOC286083, as defined by the Genome Reference Consortium GRCh37.p13 primary
human genome assembly. We also checked whether identifying genes based on LD patterns
would change the candidate genes: five genes (UNC5C, ENC1, TMEM106B, AGR3, and
LOC286083) included SNPs that were in LD with the lead SNPs, and all of these genes were
also captured by our 100-kb cutoff. All identified SNPs were either intronic or intergenic, but a
missense TMEM106B variant on Chromosome 7, rs3173615G, was in LD (r2 = 0.67) with the
local lead SNP, rs11509153. Among the lead SNPs, only rs11509153A (within TMEM106B)
exhibited a cis-eQTL effect with respect to the genes within 100 kb in the DLPFC of ROS and
MAP participants, being associated with lower expression of TMEM106B (estimated effect =
−0.22, 95% CI −0.35 to −0.10, p = 6.4 × 10−4). Three of the six genes within 100 kb from lead
Fig 1. Manhattan plot from the genome-wide association study for residual cognition. In this plot, we present the results for each SNP
tested in the genome-wide association study that included 979 participants from the Religious Orders Study and the Rush Memory and Aging
Project. Each point is one SNP. The x-axis denotes the physical position of the SNP, and the y-axis reports −log(p-value) for each SNP. The
threshold for a suggestive association (p < 10−5) is denoted by the black dotted line and identifies those loci that were considered in step 2 of
our analysis. The red dotted line denotes the threshold of genome-wide significance. The three loci considered in step 2 are highlighted:
UNC5C, ENC1, and TMEM106B.
https://doi.org/10.1371/journal.pmed.1002287.g001
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SNPs had non-zero DLPFC transcript levels in a majority (>80%) of samples from ROS and
MAP participants: UNC5C (median [first quartile–third quartile] adjusted FPKM = 1.60
[1.41–1.77]), ENC1 (adjusted FPKM = 70.10 [45.54–94.34]), and TMEM106B (adjusted
FPKM = 3.55 [2.95–4.25]). Therefore, these three genes could be evaluated in all three steps of
our analysis. Regional genetic association plots around the lead SNPs close to these genes are
depicted in Fig 2.
By contrast, consistent with our group’s prior report showing that APOE genotype loses its
effect on cognition when the analysis is controlled for pathology [50], APOE ε4 count and
APOE ε2 count were not associated with residual cognition (FDR> 0.05). Further, none of
the 19 SNPs reaching overall genome-wide significance (p< 5 × 10−8) in the International
Genomics of Alzheimer’s Project analysis [51] had an association with residual cognition
Table 2. Lead SNPs for each independent locus associated with residual cognition.
CHR Position (hg19) SNP Major Minor MAF p-Value Estimated effect Genes within 100 kb
3 105772040 rs60328885 G A 0.10 1.7 × 10−6 −0.34 —
4 96363012 rs3846455 C G 0.07 3.1 × 10−6 −0.42 UNC5C (0 kb)
5 73847916 rs76662990 A G 0.11 7.7 × 10−6 0.30 ENC1 (−75.32 kb)
7 12263800 rs11509153 G A 0.41 9.4 × 10−6 0.19 TMEM106B (0 kb)
7 16944069 rs74665712 C T 0.07 7.6 × 10−7 −0.58 AGR2 (+99.33 kb), AGR3 (+22.46 kb)
7 17065965 rs1029576 C G 0.41 4.6 × 10−6 −0.20 —
8 1216767 rs34130287 G C 0.21 4.0 × 10−6 −0.25 LOC286083 (−27.53 kb)
13 57529602 rs9527561 G A 0.46 2.2 × 10−6 −0.21 —
15 25772908 rs7402241 C T 0.04 4.5 × 10−6 −0.50 —
Estimated effect indicates change in residual cognition, as measured by z-score, per each additional minor allele of each SNP.
CHR, chromosome; MAF, minor allele frequency; SNP, single nucleotide polymorphism.
https://doi.org/10.1371/journal.pmed.1002287.t002
Fig 2. Regional genetic association plots for UNC5C, ENC1, and TMEM106B regions. In these regional plots, we present the association results
for all SNPs (dots) within each region of interest. In each region, the lead SNP is colored in purple, and other SNPs are colored based on their extent of
linkage disequilibrium with the lead SNP, following the color key included at the top right of each panel. The x-axis denotes the physical position of the
SNP, and the y-axis reports −log(p-value) for each SNP. The blue line denotes the recombination rate in this region in EUR participants from the 1000
Genomes Project. The location of the gene is presented at the bottom of the figure. (A) UNC5C region where rs3836455 (hg19 chr4:96363012) is the
lead SNP associated with residual cognition. (B) ENC1 region where rs76662990 (hg19 chr5:73847916) is the lead SNP. (C) TMEM106B region where
rs11509153 (hg19 chr7:12263800) is the lead SNP. Regional genetic association plots were plotted with LocusZoom [49].
https://doi.org/10.1371/journal.pmed.1002287.g002
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(FDR> 0.05). Finally, none of the loci associated with cognitive traits in large GWASs [52,53]
or that were cerebral cortex expression quantitative trait loci in a recent meta-analysis [54]
overlapped with the suggestive residual cognition loci from step 1.
Epigenetic and transcriptomic studies of selected genes from the
genome-wide association study
In step 2, we defined each gene’s genic region as the chromosomal segment containing the
transcribed elements of each gene ±100 kb of flanking DNA. Then, in the subset of the study
population that had DNA methylation data (n = 648), we identified CpG dinucleotides within
each genic region that were detected in our DLPFC samples using the Illumina HumanMethyla-
tion450 array [19,22]. Using the set of CpGs in each genic region, we calculated an omnibus
score that summarized the evidence of association between methylation levels and residual
cognition in each of the three genic regions, as previously described [46]. The methylation pat-
terns of UNC5C and ENC1 regions were associated with residual cognition (FDR< 0.05;
Table 3; Fig 3), and therefore these loci displayed converging evidence of genetic and epigenetic
association. These associations persisted when the analyses were controlled for the respective
genotypes implicated in residual cognition (lead SNP from step 1; Table 2): the methylation
associations are therefore not driven by the SNPs identified in step 1. In step 3, in the subset of
the study population that had DLPFC RNA-Seq data (n = 469), residual cognition was associ-
ated with mRNA levels of both UNC5C (estimated effect = −0.40, 95% CI −0.69 to −0.10, p =
0.0089) and ENC1 (estimated effect = 0.0064, 95% CI 0.0033 to 0.0096, p = 5.7 × 10−5). By con-
trast, neither the DLPFC methylation pattern nor mRNA level of TMEM106Bwas associated
with residual cognition. Thus, in our multistep analysis, two genes (UNC5C and ENC1) had
converging genetic, epigenetic, and transcriptomic evidence for a role in determining residual
cognition.
An UNC5C allele, rs3846455G, is associated with more rapid episodic
memory decline
To further characterize the two genetic regions with convergent genetic/epigenetic/transcrip-
tomic evidence, we performed additional analyses to begin to assess whether their effect may
be related to cognitive loss with advancing age or a higher cognitive attainment during devel-
opment and early life. We therefore picked the minor alleles of the lead SNPs from each of the
loci (Table 1): rs3846455G, within the first intron of UNC5C, and rs76662990G, close to ENC1.
Both SNPs were then evaluated in greater detail in relation to predicted chromatin state, base-
line cognitive scores, an individual’s pathology-adjusted slope of cognitive decline, and patho-
logical burden. Finally, we examined each SNP’s associations with previously reported
Table 3. Association of differential DNA methylation patterns with residual cognition.
Gene Number of CpGs OmniBus p-value Omnibus FDR Top CpG p-Value FDR DLPFC chromatin state
UNC5C 44 0.0025 0.008 cg10528218 0.0027 0.117 Enhancer
ENC1 40 0.0271 0.041 cg18892446 0.0032 0.129 Weak transcription
TMEM106B 23 0.0937 0.094 cg09613507 0.0086 0.199 Weak transcription
After adjustment for associated
SNP
UNC5C 44 0.0028 NA cg10528218 0.0015 0.066
ENC1 40 0.0204 NA cg18892446 0.0038 0.082
DLPFC, dorsolateral prefrontal cortex; FDR, false discovery rate.
https://doi.org/10.1371/journal.pmed.1002287.t003
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correlates of residual cognitive decline in ROS and MAP participants (depressive symptoms
[2] and composite MRI R2 score [6,7]).
According to the 15-state chromatin map model of human brain regions from the Road-
map Epigenomics Project’s Human Epigenome Atlas [43,44], rs3846455, which is found
within the first intron of UNC5C, is in a region annotated as an enhancer in multiple brain
regions, including the middle hippocampus, substantia nigra, cingulate gyrus, inferior tempo-
ral lobe, and angular gyrus. However, it is in a quiescent chromatin conformation in the
DLPFC. The frequency of the rs3846455G allele associated with lower residual cognition in
our step 1 analysis (ROS and MAP MAF = 0.07) is comparable to that reported for the 1000
Genomes Project phase 1 EUR population (MAF = 0.06) [42]. When adjusted for baseline
demographic variables, rs3846455G dosage was not associated with a participant’s baseline
global cognitive score (p> 0.05). However, after adjusting for pathology and demographic var-
iables, rs3846455G dosage was associated with more rapid global cognitive decline (estimated
effect = −0.033, 95% CI −0.050 to −0.016, p = 1.9 × 10−4). These two analyses suggest that the
detrimental effect of the UNC5C rs3846455G allele may be related to processes in later life and
is less likely to be related to developmental phenomena. The slopes of global cognitive decline
for the participants with and without the minor allele (rs3846455G) are depicted in Fig 4. We
further evaluated the rates of decline in the five cognitive domains that were included in the
global cognitive score, and the detrimental effect of the UNC5C rs3846455G allele on global
cognitive decline appears to be primarily driven by more rapid episodic memory decline (esti-
mated effect = −0.037, 95% CI −0.054 to −0.019, FDR = 2.3 × 10−4); other cognitive domains
were not associated (FDR> 0.05) (S4 Table).
In terms of pathological measures, we tested for association with rs3846455G, controlling
for age at death, sex, and study cohort. None of the ten pathological traits tested are associated
with rs3846455G dosage (FDR> 0.05), as expected given our study design. In addition, TDP-
43 stage, which was not included in our initial model, was not associated with rs3846455G dos-
age (p> 0.05).
Fig 3. Quantile–quantile plots for the association of residual cognition and DNA methylation pattern in UNC5C, ENC1, and TMEM106B
regions. Each panel presents the results of the DNA methylation analysis of one of the three tested regions: (A) UNC5C, (B) ENC1, and (C) TMEM106B.
The omnibus analysis assesses the level of evidence of association for the entire region; here, we illustrate the results by plotting the association statistic
for each CpG (dots) comparing the observed p-value to the value expected from a null distribution. The dark gray area in each plot denotes the 90%
confidence interval, and the light gray area denotes the 95% confidence interval. The functional unit of methylation is not a single CpG but rather a
methylated region, and we see that the ENC1 and UNC5C regions demonstrate a level of association that is globally different from what one would
expect by chance.
https://doi.org/10.1371/journal.pmed.1002287.g003
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For previously reported phenotypic correlates of residual cognitive decline [2,7,15], neither
depressive symptoms proximate to death (p> 0.05) nor composite R2 measures from ex vivo
brain MRI (p> 0.05) were associated with rs3846455G dosage. Similarly, we found no associa-
tion of UNC5CRNA level with either depressive symptoms proximate to death (p> 0.05) or
the composite R2 (p> 0.05). On the other hand, rs3846455G dosage was associated with the
expression of certain presynaptic proteins previously reported to be associated with residual
cognitive decline in the ROS and MAP cohorts [15]: rs3846455G was associated with lower
Complexin-I level (estimated effect = −0.33, 95% CI −0.57 to −0.09, p = 0.0073, FDR = 0.022)
but not with Complexin-II level (FDR> 0.05) or Syntaxin/SNAP-25 protein–protein interac-
tion (FDR> 0.05). Higher UNC5C RNA level was associated with lower Complexin-I level
(estimated effect = −0.69, 95% CI −1.09 to −0.30, p = 6.1 × 10−4, FDR = 0.0018), lower Com-
plexin-II level (estimated effect = −0.61, 95% CI –1.05 to −0.18, p = 0.0063, FDR = 0.0094), and
weaker Syntaxin/SNAP-25 interaction (estimated effect = −0.45, 95% CI −0.80 to −0.09, p =
0.014, FDR = 0.014). Complexin-I is enriched in GABAergic, inhibitory terminals, as is the
M18L isoform of Munc18-1, previously reported to be associated with cognitive decline in the
MAP cohort [41]. On further exploratory analyses, we also observed an effect of rs3846455G
dosage on the M18L isoform (estimated effect = −0.37, 95% CI −0.70 to −0.04, p = 0.028) but
not the M18S isoform (p> 0.05), supporting the association of UNC5C rs3846455G with
decreased inhibitory presynaptic terminal protein composition.
An ENC1 allele, rs76662990G, is associated with slower decline in
multiple cognitive domains
In the ENC1 locus, rs76662990G is the minor allele that was associated with better residual cog-
nition in our step 1 analysis. This SNP is found 75.32 kb downstream from the 30 end of ENC1,
and its MAF in ROS and MAP is 0.11, which is comparable to the 1000 Genomes Project
Fig 4. The slope of global cognitive decline by genotype. The average slope of global cognitive decline of
individuals with a certain genotype is shown, after adjusting for pathology and demographics. In both panels,
the x-axis reports years before the participant’s death, and the y-axis presents pathology-adjusted global
cognition (z-score, derived from baseline mean and standard deviation). The slope is the pathology-adjusted
residual slope of global cognitive decline, and the intercept represents mean residual cognition. (A) All
Religious Orders Study and Rush Memory and Aging Project participants are partitioned by their genotype at
rs3846455 in the UNC5C locus. Cognition is declining faster for participants with one or two copies of the
minor allele (blue line) than for individuals who are homozygous for the major allele (red line). (B) The results
for participants partitioned by rs76662990 genotype, near the ENC1 locus. Here, the presence of the minor
allele is protective against pathology-adjusted cognitive decline. Of note, we grouped participants who were
homozygotes for the minor allele together with the heterozygotes in this plot, as homozygotes were rare for
both SNPs.
https://doi.org/10.1371/journal.pmed.1002287.g004
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phase 1 EUR population MAF of 0.10. rs76662990G is in a quiescent chromatin state across
multiple brain regions per the 15-state chromatin map model generated by the Roadmap Epi-
genomics Project’s Human Epigenome Atlas [43,44]. Baseline global cognition was not associ-
ated with rs76662990G dosage (p> 0.05), after adjusting for baseline demographics. When
adjusted for pathology and demographics, rs76662990G dosage was modestly associated with a
slower rate of adjusted global cognitive decline (additive model; estimated effect = 0.016, 95%
CI 0.003 to 0.029, p = 0.018). The modest protective effect against adjusted cognitive decline
was seen in all cognitive domains except working memory (S4 Table). Thus, the locus captured
by rs76662990G seems to exert its protective effect on multiple cognitive domains (S4 Table).
As expected, none of the ten pathological traits tested were associated with rs76662990G (FDR>
0.05). Overall, like UNC5C, the ENC1 locus may be influencing processes in later life rather than
developmental processes in having an effect on residual cognition.
rs76662990G was not associated with either depressive symptoms proximate to death
(p> 0.05) or the composite R2 (p> 0.05). On the other hand, higher ENC1 RNA level in the
DLPFC, which was associated with better residual cognition, was nominally associated with
less depressive symptoms proximate to death (estimated effect = −0.0091, 95% CI −0.0165 to
−0.0017, p = 0.016) but not with the composite R2 measure (p> 0.05). For presynaptic pro-
teins, neither rs76662990G dosage nor ENC1 RNA level was associated with any of the selected
measures (FDR> 0.05).
A TMEM106B allele, rs11509153A, is associated with lower TDP-43
burden
Although the TMEM106B region showed no association with residual cognition in step 2,
rs11509153A remains of interest because it is in strong LD (r2 = 0.66) with rs1990622G, an
allele previously reported to be associated with a lower risk of TDP-43 proteinopathy [37,55].
Thus, we looked more carefully at the TMEM106B locus in our secondary analyses. The
rs11509153A allele (ROS and MAP MAF = 0.41), which was associated with better residual
cognition in step 1 (Table 1), is located in intron 4 of TMEM106B. In our study, rs11509153A
was not associated with baseline cognition (p> 0.05), but it was associated with slower pathol-
ogy-adjusted global cognitive decline (estimated effect = 0.013, 95% CI 0.005 to 0.022, p =
0.0024), and this protective effect was observed in episodic memory, semantic memory, and
working memory domains (FDR < 0.05) (S4 Table). Moreover, rs11509153A was associated
with lower TMEM106BRNA level in the DLPFC (p = 6.4 × 10−4), although TMEM106BRNA
level was not associated with residual cognition (FDR > 0.05).
Since the burden of TDP-43 proteinopathy was not available in all ROS and MAP partici-
pants at the beginning of our study, we did not include this variable when calculating residual
cognition. However, we completed a post hoc analysis in a reduced sample of 826 participants in
which we later had this variable: we explored the possibility that the association of rs11509153A
with residual cognition in step 1 was due to the burden of TDP-43 proteinopathy that had not
been accounted for in our measure of residual cognition. In this subset of participants with
TDP-43 staging, the effect size of the association between rs11509153A and residual cognition
was similar to that observed in the entire study population (estimated effect = 0.18, 95% CI 0.09
to 0.28, p = 1.3 × 10−4). In line with previous reports [37,55], rs11509153A was associated with
lower TDP-43 stage (estimated effect = −0.16, 95% CI −0.27 to −0.05, p = 0.0050), and higher
TDP-43 stage was associated with worse residual cognition (estimated effect = −0.090, 95% CI
−0.148 to −0.032, p = 0.0023) in these ROS and MAP participants. Interestingly, however, even
after controlling for TDP-43 stage, rs11509153A remained associated with residual cognition
(estimated effect = 0.17, 95% CI 0.08 to 0.26, p = 3.8 × 10−4). To examine whether a semi-
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quantitative measurement of TDP-43 severity better captured the burden of this pathological
feature, we also tested the association of rs11509153A with residual cognition while controlling
for the TDP-43 severity score: the association between rs11509153A and residual cognition
remained similar (estimated effect = 0.18, 95% CI 0.08 to 0.27, p = 2.1 × 10−4). Thus, much of the
haplotype’s protective effect was independent of the measured burden of TDP-43 proteinopathy.
We also addressed the possibility of independent effects for rs11509153A and rs1990622G
by including both SNPs in our model: rs11509153A did not have an effect beyond that cap-
tured by rs1990622G (p> 0.05), suggesting that both SNPs are likely capturing the effect of the
same functional variant. Moreover, given prior work linking the TMEM106B locus and the
granulin precursor (GRN) gene, a Mendelian risk gene for frontotemporal lobar degeneration
(FTLD) that is thought to be downstream of TMEM106B [37,47], we performed a secondary
analysis of the GRN locus: the omnibus DNA methylation (p = 0.025) and mRNA level (esti-
mated effect = −0.024, 95% CI −0.038 to −0.009, p = 0.0018) analyses of GRN revealed a modest
association with residual cognition. These findings further suggest a role for TMEM106B and
related mechanisms in influencing residual cognition in older age.
Exploratory interrogation of the loci identified in step 1
At the conclusion of our step 1 analysis, we selected genes within 100 kb from the lead SNPs
that were also expressed in DLPFC for further analyses. However, some regulatory elements
can affect genes beyond 100 kb, and we may also have missed genes that are expressed in brain
regions other than DLPFC. Thus, to test whether our analytic strategy might have missed perti-
nent candidate genes, we performed an exploratory interrogation of the lead SNPs from each
region for cis-eQTL associations using the publically available GTEx database [48]: in multiple
brain regions (anterior cingulate, frontal cortex, hippocampus, basal ganglia, cerebellum, and
hypothalamus), none of the lead SNPs were cis-eQTLs for genes within 1 Mb from the SNP.
In addition, we explored each SNP’s association with baseline cognition and pathology-
adjusted rate of global cognitive decline for the six lead SNPs from step 1 that were not further
analyzed (S5 Table). Interestingly, some of the SNPs showed some association with baseline cog-
nition (p< 0.05): rs60328885, rs1029576, rs9527561, and rs7402241. In particular, rs7402241T
displayed a highly significant association with worse baseline cognition, approaching genome-
wide significance (estimated effect = −0.37, 95% CI −0.51 to −0.24, p = 9.0 × 10−8). However,
this locus and the other five examined loci were not associated with cognitive traits in recent,
very large GWASs of cognitive performance [52,53]. Further, rs7402241T was not associated
with TDP-43 or any of the ten pathologies that we used to derive residual cognition (p> 0.05
for all pairs). Finally, all six examined loci were associated with the pathology-adjusted slope of
global cognitive decline, suggesting that they may have a role in loss of cognitive function.
Variance in cognition proximate to death is partially explained by genetic,
epigenetic, and transcriptional variations in UNC5C, ENC1, and
TMEM106B
In a subset (n = 465) of participants with all genotyping, DNA methylation, and RNA-Seq
data, we used a sequential adjusted R-squared analysis to obtain the variance in cognition
proximate to death explained by different types of variables. In this model, demographics and
common neuropathological indices explained 41.0% of the variance in global cognition proxi-
mate to death, which is consistent with prior reports from ROS and MAP [1,2]. Genetic (lead
SNPs), epigenetic (lead CpGs), and transcriptomic (RNA level) variation in UNC5C, ENC1,
and TMEM106B identified in this study explain an additional 5.9% of the variance in global
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cognition proximate to death. Still, more than half (53.1%) of the variance in cognition proxi-
mate to death remained unexplained.
Discussion
Leveraging two large community-based cohorts of older adults with genetic and phenotypic
data, this study used a multistep process including genetic, epigenetic, and expression analyses
to identify genes associated with the dissociation of cognitive function and neuropathological
burden. Our results support a potential role of UNC5C and ENC1 in modulating differential
neuronal susceptibility to pathological insults, and expand our understanding of TMEM106B,
a gene known for its association with TDP-43 proteinopathy.
UNC5C is a netrin receptor gene that mediates repulsion from netrin signal in develop-
mental neuronal migration and axonal guidance [56,57], and it also acts as a dependence
receptor that can induce apoptosis in the absence of netrin signal [58]. A recent study linked a
rare missense variant UNC5CT835M (rs137875858) to the risk of late-onset AD dementia and
reported that UNC5CT835M made neurons more susceptible to neurotoxic exposures such as
pathogenic β-amyloid 1–42, particularly in the hippocampus [59]. This study also reported
that overexpression of UNC5C (T835M as well as wild-type) was associated with increased
apoptosis and did not affect β-amyloid or extracellular tau production. Thus, our results that
identify a convergence of genetic and epigenetic evidence within the UNC5C region—and that
find increased UNC5CRNA expression to be associated with worse residual cognition—are
consistent with this previous report [59]. Moreover, in our study, more rapid decline in episodic
memory seemed to drive the association of the UNC5C allele rs3846455G with cognitive decline,
and this is consistent with the suggested selective effect of UNC5C on hippocampus [59], a brain
region critical for episodic memory. Of note, UNC5C also has a known role in neurodevelop-
ment; however, rs3846455G was not associated with variability in cognition at study entry,
making it less likely that the association between rs3846455G and residual cognition is due to
differential neurodevelopment. All in all, UNC5C is likely to be implicated in determining resid-
ual cognition through differential neuronal reaction to pathology, particularly by altering hip-
pocampal neuronal susceptibility to pathological insults. In addition, both UNC5C rs3846455G
and higher UNC5CRNA level correlated with lower presynaptic protein levels, suggesting that
the alterations in the synapses may be part of the functional consequences of the rs3846455G
risk allele and increased UNC5CRNA expression. Nonetheless, the functional mechanism of
UNC5C rs3846455G remains unclear: UNC5C rs3846455G is in a quiescent chromatin state and
does not influence RNA expression in the DLPFC, although the chromatin state of this locus is
labeled as an enhancer in middle hippocampus according to the 15-state chromatin map model
from the Roadmap Epigenomics Project’s Human Epigenome Atlas [43,44]. Also, it is unlikely
that the relationship between rs3846455G and residual cognition is driven by the rare UNC5C
T835M variant (MAF = 0.0003) in our data, as less than a single minor allele would be expected
within our entire sample of 979 participants.
ENC1, previously also known as nuclear restricted protein/brain (NRP/B), is a gene that is
highly expressed in developing neurons as well as in the adult neocortex and hippocampus in
murine models. It colocalizes with actin [60] and is implicated in neurite development and
neuronal process formation during neuronal differentiation [61]. In addition, ENC1 is impli-
cated in neural protection from various insults: ENC1 is upregulated in vitro in settings of neu-
ral injury such as oxygen-glucose deprivation [62] or toxic intracellular protein aggregation
and endoplasmic reticulum stress [63]. In these in vitro models, ENC1 upregulation is shown
to be detrimental for neural survival through its downregulation of cytoprotective genes such
as nuclear factor, erythroid 2 like 2 (NFE2L2, also known as NRF2) [62] or its downregulation
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of the autophagic pathway through interaction with phosphorylated p62 [63]. In our study,
rs76662990G was not associated with baseline cognition, which makes it less likely that
rs76662990G results in significant neurodevelopmental differences. Moreover, rs76662990G
was associated with slower cognitive decline in multiple cognitive domains, which is consistent
with widespread expression of ENC1 in the mammalian neocortex [60]. Intriguingly, contrary
to previous observations from in vitro models [62,63], we observed higher ENC1 RNA level in
participants with higher residual cognition, and higher ENC1 RNA level was also correlated
with less depressive symptoms, a known predictor of higher residual cognition [2]. Given the
complexity of in vivo pathophysiology in the human brain and the vagaries of in vitro models,
further study is required to elucidate the relationship between ENC1 expression level and
residual cognition.
In the TMEM106B locus, we found suggestive evidence of genetic association between better
residual cognition and rs11509153A, which is in a strong LD with rs1990622G, a well-known
protective allele against TDP-43 proteinopathy [37,55]. The TMEM106B haplotype captured by
rs1990622 was first identified as a risk factor for FTLD with TDP-43 proteinopathy (FTLD-
TDP) in a large GWAS [55], and later our group showed that the same haplotype is also impli-
cated in TDP-43 proteinopathy burden in older adults without FTLD [37]. In the current study,
our analyses show that rs11509153A captures the same haplotype as the rs1990622G allele,
which is protective against FTLD-TDP. Moreover, epigenetic and transcriptomic associations
with residual cognition observed at the GRN locus further suggest a role for the TMEM106B–
GRN pathway in determining residual cognition. The association of the TMEM106B haplotype
with residual cognition is plausible, as TDP-43 proteinopathy was not considered in our model
to derive residual cognition. However, neither TDP-43 staging nor a semi-quantitative TDP-43
severity score fully explains the effect of rs11509153A on residual cognition. Thus, it is possible
that the TMEM106B haplotype is related to residual cognition via multiple different processes
including processes independent of TDP-43 proteinopathy, which is in line with a prior study
reporting that the TMEM106B genotype and TDP-43 proteinopathy have independent contri-
butions to cognitive impairment in amyotrophic lateral sclerosis patients [64]. Nevertheless, it is
also possible that current TDP-43 quantification methods are not adequately capturing the bur-
den of TDP-43 proteinopathy.
With extensive data on each participant’s cognitive performance and detailed assessment of
neuropathology, the ROS and MAP cohorts are uniquely positioned for studying the phenom-
enon of differential cognitive outcomes in the setting of neuropathology, as previously shown
through multiple studies [1,2,4–7,9,14,15]. Nonetheless, our study has certain limitations.
First, step 1 of our study was underpowered to detect genome-wide significance. To circum-
vent this problem, we leveraged our prior observation that independent genetic and epigenetic
factors can converge on the same locus [19] and used a multistep approach with predefined
significance thresholds to yield credible candidate genes. In step 1, we expected enrichment of
pertinent genetic associations in the tail end of the p-value distribution, and, based on our
experiences with previous GWASs in the ROS and MAP cohorts [24,25], we selected an arbi-
trary suggestive p-value threshold of 10−5 to detect a small number of loci that could be further
tested in steps 2 and 3 without prohibitive multiple testing burden. Nonetheless, we may have
missed pertinent genetic associations if SNPs from other loci either failed to reach our step 1
threshold or did not have coexisting epigenetic associations with residual cognition. Second,
we selected genes only within 100 kb from the suggestive lead SNPs. This was to maximize sig-
nal-to-noise ratio based on the finding that most cis-regulatory elements are within 100 kb of
TSSs [45]. Nonetheless, some regulatory elements can be more distant from the TSS [45], and
we may have missed pertinent genes further than 100 kb from each SNP. However, interro-
gation of the GTEx database [48] and a previous brain eQTL meta-analysis [54] suggest that
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the loci identified in the step 1 analysis do not have regulatory roles for distant genes. Third,
we used epigenetic and transcriptomic data from DLPFC alone, leaving the possibility that we
may have missed genes that have significant roles in other brain regions or in other systems
such as the immune system. Fourth, pathological phenotypes differed in the way they were
quantified. For example, amyloid plaques and neurofibrillary tangles were counted and aver-
aged throughout multiple brain regions, thus representing rigorous quantification, whereas
other pathologies were recorded either as binary or categorical variables. The true effect of
pathologies might have not been captured due to the variable definitions. Nonetheless, besides
the TMEM106B locus—a risk factor for TDP-43 proteinopathy, which was not accounted for
in our residual cognition model—none of the loci identified through the step 1 analysis were
known genetic risk factors for the neuropathologies studied. Finally, given the limited sample
size and power of our study, future replication studies as well as experimental studies are nec-
essary to further clarify the role of the three genes identified through our study.
Despite its limitations, our study has initiated the genomic dissection of residual cognition,
identifying three genes that deserve further investigation as determinants of differential cogni-
tive outcomes in the setting of neuropathology. Further, this study supports our study design
for addressing issues of limited statistical power in deeply phenotyped participants from cohorts
of moderate size. As our results explain only a small portion of the dissociation between cogni-
tion and neuropathological burden, additional studies are required to elucidate the determi-
nants of the unexplained cognitive variability in late life.
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